Optimizing Treatment of Chronic Migraine, Part 1: Focus on Preventive Treatment
- Web Browser
- Adobe Reader
At the completion of this presentation, participants will be able to:
- Identify the principles and objectives of preventive treatment in the management of chronic migraine
- Discuss the published evidence for the preventive treatment of chronic migraine
- Discuss approaches to address failure of preventive treatment
David W. Dodick, MD, FAHS, FRCPC, FACP
Professor of Neurology
Mayo Clinic Arizona
David W. Dodick , MD, FAHS, FRCPC, FACP, is a Professor of Neurology at Mayo Clinic College of Medicine and Consultant in Neurology at Mayo Clinic in Scottsdale, Arizona.
Dr. Dodick received his medical degree with distinction from Dalhousie University in Halifax, Nova Scotia, Canada. He completed his internship and neurology residency at the Mayo Clinic in Rochester, Minnesota, followed by a fellowship at the University of Toronto, in Ontario, Canada. He is board certified in Neurology by both the Royal College of Physicians and Surgeons of Canada, and the American Board of Psychiatry and Neurology. He is also board certified in Vascular Neurology by the American Board of Psychiatry and Neurology and headache medicine by the United Council for Neurologic Subspecialties.
Dr. Dodick has authored over 250 publications and has co-authored 5 books. He is President of the American Headache Society (AHS), Editor-in-Chief of Cephalalgia and serves on the editorial board of The Neurologist, Lancet Neurology, and Postgraduate Medicine. He is currently the Program Director of the Mayo Clinic Neurology Residency and Headache Fellowship Programs in Phoenix, Arizona.
All faculty and course planners participating in continuing medical education activities sponsored by the American Headache Society® are expected to disclose to the audience any real or apparent conflict(s) of interest related to the content of their presentations. Full disclosure of faculty relationships will be presented at the beginning of each faculty presentation. In addition, all faculty are required to disclose any discussion of off-label use.
David W. Dodick, MD – Dr. Dodick has received research grants from Medtronic, ANS, The National Institutes of Health, and St. Jude. He has received consulting honoraria from Allergan, Intramed, Pfizer, Merck, Zogenix, Coherex, Neuralieve, Neuraxon, NuPathe, Boston Scientific, Novartis, Eli Lilly, and MAP Pharmaceuticals
Starr Pearlman, MS, PhD - Dr. Pearlman has received consulting honoraria from Nautilus Neuroscience, NuPathe, Neuralieve, and the American Headache Society.
Jane Saiers, PhD - Dr. Saiers has nothing to disclose.
Ms. McGillicuddy has nothing to disclose.
Ms. Taylor has nothing to disclose.
Ms. Baumer has nothing to disclose.
Ms. Traino has nothing to disclose.
Ms. Morris has nothing to disclose.
The American Headache Society designates this educational activity for a maximum of 1 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
To obtain credit, you must answer at least 3 of the 4 questions correctly on the Post-Test.
This course is valid from November 1, 2011 - November 11, 2013
Supported by an educational grant from